Corvus Pharmaceuticals Provides Updates on Mupadolimab (Anti-CD73) Programs in Oncology and Infectious Disease

Announces results published online in medRxiv in 40 patients from COVID-19 randomized controlled study, which showed primary and secondary endpoints trend toward more favorable outcome for mupadolimab treated patients vs. placebo

COVID-19 study immune response data found to be consistent with proposed mechanism

Oncology Phase 1b/2 clinical trial enrolling patients with head and neck cancers and patients with lung cancer; data anticipated at SITC meeting in November

BURLINGAME, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided an update on its development programs in oncology and infectious disease for mupadolimab (formerly CPI-006), a humanized monoclonal antibody directed against CD73 with a proposed dual mechanism of activating B cells to generate immune responses to viruses and tumor antigens, and inhibiting the production of immunosuppressive adenosine in the tumor micro environment.

Corvus is developing mupadolimab as a therapeutic for oncology indications and for infectious disease, starting with COVID-19. Today the Company announced results from its Phase 3 clinical trial of mupadolimab for COVID-19, which have been published online at medRxiv.org. The results, which cover 40 patients that were enrolled in the trial prior to its voluntary discontinuation, suggest improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. No drug related adverse events were reported in the trial.

Click the button below to read the entire Press Release:

Continue Reading The Press Release